Related Experiment Video
Updated: Jun 9, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death
Xiaowei Gong1, Zhengwen An, Yunling Wang
1Karolinska Institutet, Center for Biosciences, Department of Biosciences and Nutrition, SE-141 83 Huddinge, Sweden.
Abstract:
Resistance to anticancer drugs is often observed in prostate cancer therapy. Kindlin-2 was recently found overexpressed during cancer progression. In this study, we examined the functional role of Kindlin-2 in cisplatin-induced prostate cancer cell death. Kindlin-2 was highly expressed in the androgen-insensitive (PC-3 and DU-145), but not in the androgen-sensitive cell lines (e.g., LNCaP). Overexpression of Kindlin-2 in LNCaP protected the cells from cisplatin-induced death, while Kindlin-2 knock-down in PC-3 cells enhanced cisplatin sensitivity. Mechanistically, Kindlin-2 regulation of the anti-apoptotic Bcl-xL may explain the increased cell death in the absence of Kindlin-2. Taken together, Kindlin-2 appears to play a functional role in prostate cancer cell sensitivity to cisplatin. Targeting Kindlin-2 may therefore improve drug efficacy and reduce drug doses, and would likely be beneficial for the treatment of prostate cancer.
Insights
Kindlin-2 overexpression confers resistance to cisplatin in prostate cancer cells. Reducing Kindlin-2 levels enhances sensitivity, suggesting it as a therapeutic target for improving chemotherapy efficacy.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Anticancer drug resistance is a significant challenge in prostate cancer treatment.
- Kindlin-2 is increasingly recognized for its role in cancer progression.
Purpose of the Study:
- To investigate the functional role of Kindlin-2 in cisplatin-induced prostate cancer cell death.
- To explore the relationship between Kindlin-2 expression levels and sensitivity to cisplatin.
Main Methods:
- Assessing Kindlin-2 expression in androgen-sensitive and androgen-insensitive prostate cancer cell lines.
- Manipulating Kindlin-2 levels via overexpression and knockdown.
- Evaluating cell viability and apoptosis following cisplatin treatment.
Main Results:
- Kindlin-2 was highly expressed in androgen-insensitive (PC-3, DU-145) but not androgen-sensitive (LNCaP) prostate cancer cells.
- Kindlin-2 overexpression in LNCaP cells conferred resistance to cisplatin.
- Kindlin-2 knockdown in PC-3 cells increased sensitivity to cisplatin.
- Kindlin-2's regulation of the anti-apoptotic protein Bcl-xL was identified as a potential mechanism.
Conclusions:
- Kindlin-2 plays a critical role in modulating prostate cancer cell sensitivity to cisplatin.
- Targeting Kindlin-2 presents a potential strategy to enhance the efficacy of cisplatin-based therapies.
- Modulating Kindlin-2 could lead to improved treatment outcomes and reduced drug dosages in prostate cancer management.
